Date: 2013-07-12
Type of information: Termination of an agreement
Compound: undisclosed antibody program
Company: UCB (Belgium) Wilex (Germany)
Therapeutic area:
Type agreement:
Action mechanism:
Disease:
Details: * On July 10, 2013, UCB and Wilex have announced that UCB got access to an antibody program from the Wilex preclinical portfolio originally obtained from UCB in 2009. UCB has the right to develop the antibodies from the programme in any indication outside the field of oncology, while Wilex keeps the rights to develop for oncology indications. Wilex will be reimbursed an undisclosed amount for its development costs to date and shall be eligible for future, undisclosed development, regulatory and commercial milestone payments and royalties.
UCB and Wilex will continue to share data regarding the programme through the existing development committee structures. UCB will be working on these antibodies in immunology/inflammation and, as part of the strategic partnership between the two companies, will make available to Wilex the relevant data to assist Wilex in oncology.
Financial terms:
Latest news: * On May 21, 2014, Wilex announced that due to the strategic re-alignment implemented at WILEX AG, the collaboration agreement for the clinical product candidates WX-554 and WX-037 and for three preclinical antibody programmes has been terminated by mutual agreement. Furthermore this agreement regarding an antibody programme for non-oncology indications signed last year has been terminated.
